Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature

NCT06470243 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT06470243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06470243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Recruiting
Start date
November 27, 2024
Completion date
April 30, 2034
Enrollment
528 (estimated)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, stage ivb prostate cancer ajcc v8